<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-one patients with cerebral <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> were treated for twelve months with placebo or cyclandelate (Cyclospasmol), 400 mg four times daily, in a double-blind study with medication cross-over after six months </plain></SENT>
<SENT sid="1" pm="."><plain>The group included 8 men and 13 women, with a mean age of 69 years </plain></SENT>
<SENT sid="2" pm="."><plain>Each patient showed at least 5 of 9 signs or symptoms adopted as "inclusion criteria" for the study </plain></SENT>
<SENT sid="3" pm="."><plain>Concomitant psychotropic or other drug therapy was standardized or matched during the trial, and periodic assessments were made of the patients' behavioral, physical, neurologic and psychiatric status </plain></SENT>
<SENT sid="4" pm="."><plain>No serious side effects were observed </plain></SENT>
<SENT sid="5" pm="."><plain>There was no significant difference between the cyclandelate and placebo phases in measurements of physical state </plain></SENT>
<SENT sid="6" pm="."><plain>Changes on the gross behavior scales were insufficient for analysis </plain></SENT>
<SENT sid="7" pm="."><plain>Tests of memory, control of manual dexterity and comprehension of everyday situations showed statistically significant improvement during the cyclandelate phase </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast to placebo, no measurable intellectual decline occurred during cyclandelate therapy </plain></SENT>
</text></document>